Envista to acquire Osteogenics Biomedical Business

Envista Holdings Corporation has entered into a definitive agreement to acquire Osteogenics Biomedical Inc, Allotech LLC and OBI Biologics, Inc (together “Osteogenics”). The transaction is subject to customary regulatory approvals and expected to close in the third quarter.

Osteogenics is a developer of regenerative solutions for periodontists, oral & maxillofacial surgeons, and clinicians involved in implant dentistry throughout the world. Primarily sold under the Cytoplast brand name, Osteogenics offers a complete line of bone grafting products. Bone grafting and regenerative therapies are often a critical step in implant-based tooth replacements. By improving bone stability, regenerative solutions support better clinical outcomes for more patients.

Envista’s CEO Amir Aghdaei said: “Increasing our capabilities in regenerative solutions is consistent with our intention to digitise, personalise, and democratise oral care. Osteogenics is a recognised pioneer in membrane technologies used in dental bone grafting procedures. They are a trusted brand and have a proven track record of growth. We are excited to welcome the Osteogenics team to Envista.”